The "omics" — genomics, transcriptomics, metabolomics and proteomics — are booming in biotech, with more big raises expected in 2023.
Venture
Dealmakers think 2023 could see a significant jump in M&A volume as companies’ options for money and exits dwindle.
Despite 2022's pullback in venture capital funding, 10 companies in the U.S. still broke the $1 billion barrier in individual raises.
For 2023, we’re predicting that startup investors will be looking for novelty in the companies they back. Out with the me-too business plans.
Venture firms have continued to raise record funds in 2022, even as startups received far less money. So what will happen with all that dry powder in...
With layoffs, massive funding pullbacks and an overall sense of doom clouding the economy, we naturally saw attention drawn to our coverage of those...
Now that the end of the year is fast approaching, let’s look at the five most interesting rounds of the year — at least in our eyes.
We here at Crunchbase love to talk about billions — billions in valuations, billions in revenue and billions in fundraising, even in a volatile year...
For startups in times like these, Series A is a good place to be. However, given the dropoff after Series A, startups might get stuck unless Series B...
With the world’s eyes on Argentina, it’s an opportune time to look at a space that gets way less attention than soccer: the Argentine startup scene.
Follow along with the Crunchbase News team as we track the major events of a year full of hairpin turns.
67.1K Followers